newsfilter
← Latest News
GlobeNewswire·

Landos Biopharma Announces First Subject Dosed in a Phase 1 Study of LABP-104 for Systemic Lupus Erythematosus

Topline results are expected in the first half of 2022 A whole blood LABP-104 precision medicine signature will be assessed during the trial BLACKSBURG, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a late-clinical